Study of XNW28012 for advanced pancreatic cancer after prior treatments
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, XNW28012, for people with advanced pancreatic cancer that has worsened after two standard chemotherapy treatments. The drug targets a protein called tissue factor on cancer cells, which might help slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread to other parts of the body.
- Your cancer has worsened after at least two standard chemotherapy treatments.
- You are 18 years or older.
- You have a tumor that can be measured on scans.
- You are willing to provide a tissue sample to check for tissue factor.
- You are generally well enough to be mobile and care for yourself.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (FG-M108) combined with chemotherapy for pancreatic cancer that is advanced or has spread. The medicine targets a protein found on some pancreatic cancer cells, and the goal is to see if it helps shrink tumors or slow the cancer more than chemotherapy alone.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.